Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Immunisation against infectious diseases
This is the third edition of this publication which contains the latest information on vaccines and vaccination procedures for all the vaccine preventable infectious diseases that may occur in the UK or in travellers going outside of the UK, particularly those immunisations that comprise the routine immunisation programme for all children from birth to adolescence. It is divided into two sections: the first section covers principles, practices and procedures, including issues of consent, contraindications, storage, distribution and disposal of vaccines, surveillance and monitoring, and the Vaccine Damage Payment Scheme; the second section covers the range of different diseases and vaccines.
Hepatitis B Virus and Liver Disease
This book provides a comprehensive, state-of-the art review of HBV infection and liver disease. It discusses new data on basic and translational medicine, including the viral life cycle, the immunopathogenesis of virus-induced chronic hepatitis, viral and host genetic factors affecting disease progression, and the mechanism of virus-induced hepatocarcinogenesis, as well as their potential applications in daily clinical practice. The clinical aspects of chronic HBV infection are examined in chapters on the global epidemiology, efficacy of HBV vaccination, natural history, co-infections with HCV, HDV or HIV, and management of special populations including children, pregnant women and patients undergoing immunosuppressive therapy. Further, it describes the advances and perspectives in the development of novel antiviral treatments as possible cures for HBV infection. The book is a valuable resource for medical students, physicians, and researchers who are interested in managem ent of patients with chronic HBV infection and investigation of HBV infection.
Hepatitis B
Toby K. Eisenstein Symposium Committee Chairperson Temple University School of Medicine Philadelphia, Pennsylvania 19140 This symposium is the thirteenth biennial clinical microbiology program sponsored by the Eastern Pennsylvania Branch of the American Society for Microbiology in cooperation with the Philadelphia area medical schools and the Bureau of Laboratories of the Pennsylvania Department of Health. This year a generous contribution from Merck, Sharp and Dohme has helped to make the program a reality. The subject matter for this symposium represents an attractive spectrum of medical, biological and molecular approaches to the practical solution of a public health prob1em--name1y, prevention of infection with the hepatitis B virus. The symposium may be unique in that it focuses on a product which was first marketed less than three months ago, but included in the program are presen tations on two new approaches to hepatitis B vaccine production which may replace the one which is newly unveiled. The rapidity of progress in our present era of biological research is indeed astonishing.
CDC Yellow Book 2018: Health Information for International Travel
An up-to-date, definitive guide to staying safe and healthy anywhere in the world. Completely updated for 2018 with expanded guidelines for Zika virus, cholera vaccine, and more.
Adverse Effects of Vaccines
In 1900, for every 1,000 babies born in the United States, 100 would die before their first birthday, often due to infectious diseases. Today, vaccines exist for many viral and bacterial diseases. The National Childhood Vaccine Injury Act, passed in 1986, was intended to bolster vaccine research and development through the federal coordination of vaccine initiatives and to provide relief to vaccine manufacturers facing financial burdens. The legislation also intended to address concerns about the safety of vaccines by instituting a compensation program, setting up a passive surveillance system for vaccine adverse events, and by providing information to consumers. A key component of the legis...
Guidelines on Hepatitis B and C Testing
Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.
Hepatitis B
About 375 million people are infected with the hepatitis B virus. It has killed more people than AIDS and also causes millions of cases of liver cancer. The discovery of this deadly virus and the vaccine against it--a vaccine that is sharply decreasing the infection rate worldwide and is probably the first effective cancer vaccine--was one of the great triumphs of twentieth-century medicine. And it almost didn't happen. With wit and insight, this scientific memoir and story of discovery describes how Baruch Blumberg and a team of researchers found a virus they were not looking for and created a vaccine for a disease they previously knew little about--work that took the author around the worl...
Hepatitis B Virus
None
Hepatitis and Liver Cancer
The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require ...
Hepatitis B
None
